Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rhythm BiosciencesASX:RHY +2.35% Days Payable is 387.93 as of Jun. 2026, which is 25% below its 10-year median of 519.67. The stock has 1 warning sign investors should review. Among 191 Medical Diagnostics & Research companies, Rhythm Biosciences ranks better than 93.72% on this metric.
The historical rank and industry rank for Rhythm Biosciences's Days Payable or its related term are showing as below:
ASX:RHY'
s Days Payable Range Over the Past 10 Years
Min: 437.49 Med: 519.67 Max: 601.84
Current: 459.29
During the past 9 years, Rhythm Biosciences's highest Days Payable was 601.84. The lowest was 437.49. And the median was 519.67.
ASX:RHY's Days Payable is ranked better than 93.72% of 191
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.6
vs ASX:RHY: 459.29
Rhythm Biosciences's Days Payable
increased
from Jun. 2025 (0.00) to Jun. 2026 (387.93).
It may suggest that Rhythm Biosciencesdelayed paying its suppliers.
The historical data trend for Rhythm Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:RHY vs TMO, DHR, NTRA: Days Payable Comparison
For the Diagnostics & Research subindustry, Rhythm Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Rhythm Biosciences's Days Payable for the fiscal year that ended in Jun. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Biosciences (ASX:RHY) has a Days Payable of 387.93 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rhythm Biosciences and its competitors. This is 25% below median its historical median of 519.67. Over the past decade, Rhythm Biosciences' Days Payable has ranged from 437.49 to 601.84. According to the industry distribution chart, Rhythm Biosciences ranks #12 out of 191 companies in the Medical Diagnostics & Research industry, placing it in the top 6.3%.
Is Rhythm Biosciences' Days Payable too high?
Rhythm Biosciences' current Days Payable of 387.93 is 25% below median its 10-year median of 519.67. Over the past 10 years, this metric has ranged from a low of 437.49 to a high of 601.84. The Medical Diagnostics & Research industry median Days Payable is 67.60. Rhythm Biosciences' value of 387.93 is 473.9% above this industry median. Based on the distribution chart, Rhythm Biosciences ranks #12 out of 191 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Rhythm Biosciences' Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #12 out of 191 companies for Days Payable. This places Rhythm Biosciences in the top 6% of its industry — outperforming the majority of peers. The industry median Days Payable is 67.60. Rhythm Biosciences' value of 387.93 is 473.9% above this benchmark. Historically, Rhythm Biosciences' own Days Payable has ranged from 437.49 to 601.84 over the past decade. While the company's 10-year median is 519.67 vs. the industry median of 67.60, Rhythm Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.60, based on 191 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Biosciences's current Days Payable of 387.93 is 473.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current Days Payable is 387.93, which is 25% below median its own 10-year median of 519.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (ASX:RHY) has a current Days Payable of 387.93. The current Days Payable is 387.93, which is 25% below median its 10-year median of 519.67 and 473.9% above the Medical Diagnostics & Research industry median of 67.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Rhythm Biosciences (ASX:RHY), the current Days Payable is 387.93 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:RHY has been successfully added to your 
